LeafNLP Demos
Back to explore

Report #2889633

Received Mar 18, 2026

Reports are unverified and do not show that a vaccine caused an event. Full disclaimer

Overview

Sex
Unknown
Age
Age unknown
State
—
Recovered
Unknown
Vaccinated
—
Onset
—
Days to onset
—
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
TYPTYPHOID LIVE ORAL TY21A (VIVOTIF)BERNA BIOTECH, LTD.2Unknown—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

The patient took Vivotif vaccine for two consecutive days; Case reference number US-BN-2025-001036 is a spontaneous case initially received from a consumer via Communications (reference number: USBAV25-1348) on 09-Jun-2025 and concerns a patient of unknown age and gender. The patient's medical history and concomitant medication details were not provided. On unspecified date, the patient took Vivotif vaccine for two consecutive days (batch number: unknown), at unknown doses, route, or site of administration for an unknown indication (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine. Additional information received from consumer on 10-Jun-2025: Information included confirmation of dose administration.; Reporter's Comments: A patient of unknown age and gender took Vivotif vaccine for two consecutive days, at unknown doses, route, or site of administration for an unknown indication which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif vaccine. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A patient of unknown age and gender took Vivotif vaccine for two consecutive days, at unknown doses, route, or site of administration for an unknown indication which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif vaccine. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.

Medical history

Comments: None.